论文部分内容阅读
目的：探讨冻干人胎盘因子(PF)对肿瘤化学治疗(化疗)病人外周血象的影响。方法：共收治69例,采用自身交叉随机对照研究,即均接受2个疗程相同方案的化疗,其中一个疗程为化疗+PF (化疗+PF组),另一个疗程单用化疗(单用化疗组)。化疗+PF组d1开始用PF,隔日1次,每次18mg,im,持续3～4wk。结果：化疗后白细胞(WBC)最低点：化疗+PF组为(3．0±s 1．1)×10~9·L~(-1),单用化疗组为(2．6±1．2)×10~9·L~(-1)(P＜0．01)；WBC恢复时间：化疗+PF组和单用化疗组分别为(5±4)d和(11±20)d(P=0．005)。未发现不良反应。结论：PF可改善化疗所引起的骨髓抑制,有助提高化疗的耐受性。
Objective: To investigate the effect of lyophilized human placental factor (PF) on peripheral blood of chemotherapy-treated patients. Methods: A total of 69 patients were enrolled in this study. They were randomized, cross-over, and randomized to receive two courses of chemotherapy with the same regimen. One course of chemotherapy was chemotherapy + PF (chemotherapy + PF) and the other was chemotherapy alone ). Chemotherapy + PF group d1 started with PF, every other day 1, each 18mg, im, lasting 3 ~ 4wk. Results: The lowest point of WBC after chemotherapy was (3.0 ± s 1.1) × 10 ~ 9 · L -1 in chemotherapy + PF group and (2.6 ± 1) in chemotherapy alone group. 2) × 10 ~ 9 · L -1 (P <0.01); WBC recovery time was (5 ± 4) days and (11 ± 20) days P = 0.005). No adverse reactions found. Conclusion: PF can improve the myelosuppression caused by chemotherapy, and help to improve the chemotherapy tolerance.